Philip L. Felgner

About

Philip L. Felgner is a pioneering figure in proteomics and vaccine development, best known for his transformative work on protein microarray technology. His key research areas include infectious disease immunology, vaccine target discovery, and high-throughput proteome analysis. Felgner’s major contribution is the development of proteome microarrays, which enable the comprehensive profiling of humoral immune responses to pathogens. His seminal 2005 paper, cited over 420 times, introduced a high-throughput PCR recombination cloning and expression platform that bypassed the bottleneck of producing complete proteomes from pathogen genomes, revolutionizing the discovery of vaccine and diagnostic antigens. This work has had a profound impact on the study of malaria, tuberculosis, and other infectious diseases. Felgner also contributed to the evaluation of the RTS,S malaria vaccine, providing serologic evidence of decreased exposure to *Plasmodium falciparum* parasites, and innovated transcriptionally active PCR (TAP) for rapid gene expression studies. With a career spanning decades, Felgner’s technologies have accelerated the identification of immune targets and shaped modern vaccinology, making him a highly cited and influential researcher whose tools are now standard in immunoproteomics.

Research Focus

Key Achievements

Top Papers

1. 1
   Profiling the humoral immune response to infection by using proteome microarrays: High-throughput vaccine and diagnostic antigen discovery

   421 citations · 2005
2. 2
   RTS,S Vaccination Is Associated With Serologic Evidence of Decreased Exposure to Plasmodium falciparum Liver- and Blood-Stage Parasites*

   39 citations · 2014
3. 3
   Transcriptionally Active Polymerase Chain Reaction (TAP)

   36 citations · 2002

Key Collaborators

Contact & Links